Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10224MR)

This product GTTS-WQ10224MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001127691.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6007
UniProt ID Q02161
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10224MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13628MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ7798MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ3200MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ11321MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ13244MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ9253MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ6723MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ9483MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW